{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:07:28Z","timestamp":1793995648124,"version":"4.8.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-20-CE16-0016."],"award-info":[{"award-number":["ANR-20-CE16-0016."]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Phosphodiesterases (PDEs) are enzymes involved in the homeostasis of both cAMP and cGMP. They are members of a family of proteins that includes 11 subfamilies with different substrate specificities. Their main function is to catalyze the hydrolysis of cAMP, cGMP, or both. cAMP and cGMP are two key second messengers that modulate a wide array of intracellular processes and neurobehavioral functions, including memory and cognition. Even if these enzymes are present in all tissues, we focused on those PDEs that are expressed in the brain. We took into consideration genetic variants in patients affected by neurodevelopmental disorders, phenotypes of animal models, and pharmacological effects of PDE inhibitors, a class of drugs in rapid evolution and increasing application to brain disorders. Collectively, these data indicate the potential of PDE modulators to treat neurodevelopmental diseases characterized by learning and memory impairment, alteration of behaviors associated with depression, and deficits in social interaction. Indeed, clinical trials are in progress to treat patients with Alzheimer\u2019s disease, schizophrenia, depression, and autism spectrum disorders. Among the most recent results, the application of some PDE inhibitors (PDE2A, PDE3, PDE4\/4D, and PDE10A) to treat neurodevelopmental diseases, including autism spectrum disorders and intellectual disability, is a significant advance, since no specific therapies are available for these disorders that have a large prevalence. In addition, to highlight the role of several PDEs in normal and pathological neurodevelopment, we focused here on the deregulation of cAMP and\/or cGMP in Down Syndrome, Fragile X Syndrome, Rett Syndrome, and intellectual disability associated with the\n                    <jats:italic>CC2D1A<\/jats:italic>\n                    gene.\n                  <\/jats:p>","DOI":"10.1038\/s41380-020-00997-9","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T12:03:52Z","timestamp":1610021032000},"page":"4570-4582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":154,"title":["Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3598-7688","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Delhaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6411-1517","authenticated-orcid":false,"given":"Barbara","family":"Bardoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"997_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1210\/er.2013-1053","volume":"35","author":"MF Azevedo","year":"2014","unstructured":"Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev. 2014;35:195\u2013233.","journal-title":"Endocr Rev."},{"key":"997_CR2","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.bbadis.2014.08.012","volume":"1842","author":"C Steegborn","year":"2014","unstructured":"Steegborn C. Structure, mechanism, and regulation of soluble adenylyl cyclases - similarities and differences to transmembrane adenylyl cyclases. Biochim Biophys Acta. 2014;1842:2535\u201347.","journal-title":"Biochim Biophys Acta."},{"key":"997_CR3","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.cellsig.2011.09.001","volume":"23","author":"LR Potter","year":"2011","unstructured":"Potter LR. Guanylyl cyclase structure, function and regulation. Cell Signal. 2011;23:1921\u20136.","journal-title":"Cell Signal"},{"key":"997_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","volume":"58","author":"AT Bender","year":"2006","unstructured":"Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58:488\u2013520.","journal-title":"Pharmacol Rev"},{"key":"997_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.molcel.2004.07.005","volume":"15","author":"KYJ Zhang","year":"2004","unstructured":"Zhang KYJ, Card GL, Suzuki Y, Artis DR, Fong D, Gillette S, et al. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell. 2004;15:279\u201386.","journal-title":"Mol Cell"},{"key":"997_CR6","doi-asserted-by":"publisher","first-page":"eaal3321","DOI":"10.1126\/science.aal3321","volume":"356","author":"PJ Thul","year":"2017","unstructured":"Thul PJ, \u00c5kesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, et al. A subcellular map of the human proteome. Science. 2017;356:eaal3321.","journal-title":"Science."},{"key":"997_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.cell.2018.06.021","volume":"174","author":"A Zeisel","year":"2018","unstructured":"Zeisel A, Hochgerner H, L\u00f6nnerberg P, Johnsson A, Memic F, van der Zwan J, et al. Molecular architecture of the mouse nervous system. Cell. 2018;174:999\u20131014.e22.","journal-title":"Cell."},{"key":"997_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","volume":"59","author":"V Lakics","year":"2010","unstructured":"Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology. 2010;59:367\u201374.","journal-title":"Neuropharmacology."},{"key":"997_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/nn997","volume":"6","author":"JA Esteban","year":"2003","unstructured":"Esteban JA, Shi S-H, Wilson C, Nuriya M, Huganir RL, Malinow R. PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. Nat Neurosci. 2003;6:136\u201343.","journal-title":"Nat Neurosci."},{"key":"997_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1101\/lm.5.3.231","volume":"5","author":"H Son","year":"1998","unstructured":"Son H, Lu YF, Zhuo M, Arancio O, Kandel ER, Hawkins RD. The specific role of cGMP in hippocampal LTP. Learn Mem. 1998;5:231\u201345.","journal-title":"Learn Mem."},{"key":"997_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1523\/JNEUROSCI.20-01-00089.2000","volume":"20","author":"TG Banke","year":"2000","unstructured":"Banke TG, Bowie D, Lee H, Huganir RL, Schousboe A, Traynelis SF. Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J Neurosci. 2000;20:89\u2013102.","journal-title":"J Neurosci."},{"key":"997_CR12","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1126\/science.1179735","volume":"327","author":"M Shelly","year":"2010","unstructured":"Shelly M, Lim BK, Cancedda L, Heilshorn SC, Gao H, Poo M. Local and long-range reciprocal regulation of cAMP and cGMP in axon\/dendrite formation. Science. 2010;327:547\u201352.","journal-title":"Science."},{"key":"997_CR13","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1523\/JNEUROSCI.3596-15.2016","volume":"36","author":"H Akiyama","year":"2016","unstructured":"Akiyama H, Fukuda T, Tojima T, Nikolaev VO, Kamiguchi H. Cyclic nucleotide control of microtubule dynamics for axon guidance. J Neurosci. 2016;36:5636\u201349.","journal-title":"J Neurosci."},{"key":"997_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1177\/1073858411418525","volume":"18","author":"DC Crawford","year":"2012","unstructured":"Crawford DC, Mennerick S. Presynaptically silent synapses: dormancy and awakening of presynaptic vesicle release. Neuroscientist. 2012;18:216\u201323.","journal-title":"Neuroscientist."},{"key":"997_CR15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/978-3-540-68964-5_24","volume":"191","author":"T Kleppisch","year":"2009","unstructured":"Kleppisch T, Feil R. cGMP signalling in the mammalian brain: role in synaptic plasticity and behaviour. Handb Exp Pharmacol. 2009;191:549\u201379.","journal-title":"Handb Exp Pharmacol"},{"key":"997_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3389\/fncel.2014.00376","volume":"8","author":"S Averaimo","year":"2014","unstructured":"Averaimo S, Nicol X. Intermingled cAMP, cGMP and calcium spatiotemporal dynamics in developing neuronal circuits. Front Cell Neurosci. 2014;8:376.","journal-title":"Front Cell Neurosci."},{"key":"997_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1523\/JNEUROSCI.4478-05.2006","volume":"26","author":"T Kumada","year":"2006","unstructured":"Kumada T, Lakshmana MK, Komuro H. Reversal of neuronal migration in a mouse model of fetal alcohol syndrome by controlling second-messenger signalings. J Neurosci. 2006;26:742\u201356.","journal-title":"J Neurosci."},{"key":"997_CR18","doi-asserted-by":"publisher","first-page":"eaba3992","DOI":"10.1126\/sciadv.aba3992","volume":"6","author":"J Stoufflet","year":"2020","unstructured":"Stoufflet J, Chaulet M, Doulazmi M, Fouquet C, Dubacq C, M\u00e9tin C, et al. Primary cilium-dependent cAMP\/PKA signaling at the centrosome regulates neuronal migration. Sci Adv. 2020;6:eaba3992.","journal-title":"Sci Adv."},{"key":"997_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.tins.2005.06.005","volume":"28","author":"WA Carlezon","year":"2005","unstructured":"Carlezon WA, Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci. 2005;28:436\u201345.","journal-title":"Trends Neurosci."},{"key":"997_CR20","first-page":"140","volume":"4","author":"S Portis","year":"2012","unstructured":"Portis S, Giunta B, Obregon D, Tan J. The role of glycogen synthase kinase-3 signaling in neurodevelopment and fragile X syndrome. Int J Physiol Pathophysiol Pharmacol. 2012;4:140\u20138.","journal-title":"Int J Physiol Pathophysiol Pharmacol."},{"key":"997_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1440-169X.2006.00889.x","volume":"48","author":"Z Li","year":"2006","unstructured":"Li Z, Theus MH, Wei L. Role of ERK 1\/2 signaling in neuronal differentiation of cultured embryonic stem cells. Dev Growth Differ. 2006;48:513\u201323.","journal-title":"Dev Growth Differ."},{"key":"997_CR22","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.3390\/ijms21124471","volume":"21","author":"H Albert-Gasc\u00f3","year":"2020","unstructured":"Albert-Gasc\u00f3 H, Ros-Bernal F, Castillo-G\u00f3mez E, Olucha-Bordonau FE. MAP\/ERK signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes. Int J Mol Sci. 2020;21:4471.","journal-title":"Int J Mol Sci."},{"key":"997_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1460-9568.2010.07273.x","volume":"32","author":"C Spilker","year":"2010","unstructured":"Spilker C, Kreutz MR. RapGAPs in brain: multipurpose players in neuronal Rap signalling. Eur J Neurosci. 2010;32:1\u20139.","journal-title":"Eur J Neurosci."},{"key":"997_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1515\/hsz-2015-0270","volume":"397","author":"J Zhong","year":"2016","unstructured":"Zhong J. RAS and downstream RAF-MEK and PI3K-AKT signaling in neuronal development, function and dysfunction. Biol Chem. 2016;397:215\u201322.","journal-title":"Biol Chem."},{"key":"997_CR25","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41588-018-0147-3","volume":"50","author":"JJ Lee","year":"2018","unstructured":"Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat Genet. 2018;50:1112\u201321.","journal-title":"Nat Genet."},{"key":"997_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fnmol.2019.00022","volume":"12","author":"ME Gurney","year":"2019","unstructured":"Gurney ME. Genetic association of phosphodiesterases with human cognitive performance. Front Mol Neurosci. 2019;12:22.","journal-title":"Front Mol Neurosci."},{"key":"997_CR27","doi-asserted-by":"publisher","first-page":"14160","DOI":"10.1016\/S0021-9258(18)66997-2","volume":"261","author":"RK Sharma","year":"1986","unstructured":"Sharma RK, Wang JH. Purification and characterization of bovine lung calmodulin-dependent cyclic nucleotide phosphodiesterase. An enzyme containing calmodulin as a subunit. J Biol Chem. 1986;261:14160\u20136.","journal-title":"J Biol Chem."},{"key":"997_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-017-0137-9","volume":"8","author":"Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium.","year":"2017","unstructured":"Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium. Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia. Mol Autism. 2017;8:21.","journal-title":"Mol Autism."},{"key":"997_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nature13772","volume":"515","author":"S De Rubeis","year":"2014","unstructured":"De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515:209\u201315.","journal-title":"Nature."},{"key":"997_CR30","doi-asserted-by":"publisher","first-page":"S288","DOI":"10.1016\/j.schres.2019.11.041","volume":"216","author":"J John","year":"2020","unstructured":"John J, Bhattacharyya U, Yadav N, Kukshal P, Bhatia T, Nimgaonkar VL, et al. Multiple rare inherited variants in a four generation schizophrenia family offer leads for complex mode of disease inheritance. Schizophrenia Res. 2020;216:S288\u2013294.","journal-title":"Schizophrenia Res."},{"key":"997_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fnmol.2019.00021","volume":"12","author":"S McQuown","year":"2019","unstructured":"McQuown S, Xia S, Baumg\u00e4rtel K, Barido R, Anderson G, Dyck B, et al. Phosphodiesterase 1b (PDE1B) regulates spatial and contextual memory in hippocampus. Front Mol Neurosci. 2019;12:21.","journal-title":"Front Mol Neurosci"},{"key":"997_CR32","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1523\/JNEUROSCI.22-12-05188.2002","volume":"22","author":"TM Reed","year":"2002","unstructured":"Reed TM, Repaske DR, Snyder GL, Greengard P, Vorhees CV. Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. J Neurosci. 2002;22:5188\u201397.","journal-title":"J Neurosci"},{"key":"997_CR33","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00213-017-4587-8","volume":"234","author":"JR Hufgard","year":"2017","unstructured":"Hufgard JR, Williams MT, Skelton MR, Grubisha O, Ferreira FM, Sanger H, et al. Phosphodiesterase-1b (Pde1b) knockout mice are resistant to forced swim and tail suspension induced immobility and show upregulation of Pde10a. Psychopharmacology. 2017;234:1803\u201313.","journal-title":"Psychopharmacology."},{"key":"997_CR34","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/mds.28023","volume":"35","author":"Z Haidar","year":"2020","unstructured":"Haidar Z, Jalkh N, Corbani S, Abou-Ghoch J, Fawaz A, Mehawej C, et al. A homozygous splicing mutation in PDE2A in a family with atypical Rett syndrome. Mov Disord. 2020;35:896\u20139.","journal-title":"Mov Disord."},{"key":"997_CR35","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/mds.27286","volume":"33","author":"V Salpietro","year":"2018","unstructured":"Salpietro V, Perez-Due\u00f1as B, Nakashima K, San Antonio-Arce V, Manole A, Efthymiou S, et al. A homozygous loss-of-function mutation in PDE2A associated to early-onset hereditary chorea. Mov Disord. 2018;33:482\u20138.","journal-title":"Mov Disord."},{"key":"997_CR36","doi-asserted-by":"publisher","first-page":"109592","DOI":"10.1016\/j.cellsig.2020.109592","volume":"70","author":"R Farmer","year":"2020","unstructured":"Farmer R, Burbano SD, Patel NS, Sarmiento A, Smith AJ, Kelly MP. Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease. Cell Signal. 2020;70:109592.","journal-title":"Cell Signal."},{"key":"997_CR37","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/cvr\/cvy030","volume":"114","author":"MR Assenza","year":"2018","unstructured":"Assenza MR, Barbagallo F, Barrios F, Cornacchione M, Campolo F, Vivarelli E, et al. Critical role of phosphodiesterase 2A in mouse congenital heart defects. Cardiovasc Res. 2018;114:830\u201345.","journal-title":"Cardiovasc Res."},{"key":"997_CR38","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1517\/14728222.2013.818656","volume":"17","author":"W Richter","year":"2013","unstructured":"Richter W, Menniti FS, Zhang H-T, Conti M. PDE4 as a target for cognition enhancement. Expert Opin Ther Targets. 2013;17:1011\u201327.","journal-title":"Expert Opin Ther Targets."},{"key":"997_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/289079a0","volume":"289","author":"D Byers","year":"1981","unstructured":"Byers D, Davis RL, Kiger JA. Defect in cyclic AMP phosphodiesterase due to the dunce mutation of learning in Drosophila melanogaster. Nature. 1981;289:79\u201381.","journal-title":"Nature."},{"key":"997_CR40","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.neuron.2010.01.014","volume":"65","author":"N Gervasi","year":"2010","unstructured":"Gervasi N, Tch\u00e9nio P, Preat T. PKA dynamics in a Drosophila learning center: coincidence detection by rutabaga adenylyl cyclase and spatial regulation by dunce phosphodiesterase. Neuron. 2010;65:516\u201329.","journal-title":"Neuron."},{"key":"997_CR41","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1126\/science.1112915","volume":"310","author":"JK Millar","year":"2005","unstructured":"Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science. 2005;310:1187\u201391.","journal-title":"Science."},{"key":"997_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/YPG.0b013e328014492b","volume":"17","author":"BS Pickard","year":"2007","unstructured":"Pickard BS, Thomson PA, Christoforou A, Evans KL, Morris SW, Porteous DJ, et al. The PDE4B gene confers sex-specific protection against schizophrenia. Psychiatr Genet. 2007;17:129\u201333.","journal-title":"Psychiatr Genet."},{"key":"997_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3934\/genet.2019.3.55","volume":"6","author":"AV Malakhova","year":"2019","unstructured":"Malakhova AV, Rudko OI, Sobolev VV, Tretiakov AV, Naumova EA, Kokaeva ZG, et al. PDE4B gene polymorphism in Russian patients with panic disorder. AIMS Genet. 2019;6:55\u201363.","journal-title":"AIMS Genet."},{"key":"997_CR44","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00213-007-0727-x","volume":"192","author":"JA Siuciak","year":"2007","unstructured":"Siuciak JA, Chapin DS, McCarthy SA, Martin AN. Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology. 2007;192:415\u201324.","journal-title":"Psychopharmacology."},{"key":"997_CR45","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.neuropharm.2011.03.020","volume":"61","author":"K Rutten","year":"2011","unstructured":"Rutten K, Wallace TL, Works M, Prickaerts J, Blokland A, Novak TJ, et al. Enhanced long-term depression and impaired reversal learning in phosphodiesterase 4B-knockout (PDE4B-\/-) mice. Neuropharmacology. 2011;61:138\u201347.","journal-title":"Neuropharmacology."},{"key":"997_CR46","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/sj.npp.1301537","volume":"33","author":"H-T Zhang","year":"2008","unstructured":"Zhang H-T, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L, et al. Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology. 2008;33:1611\u201323.","journal-title":"Neuropsychopharmacology."},{"key":"997_CR47","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1210\/jc.2012-2326","volume":"97","author":"A Linglart","year":"2012","unstructured":"Linglart A, Fryssira H, Hiort O, Holterhus P-M, Perez de Nanclares G, Argente J, et al. PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct syndromes with or without GPCR-signaling hormone resistance. J Clin Endocrinol Metab. 2012;97:2328\u201338.","journal-title":"J Clin Endocrinol Metab."},{"key":"997_CR48","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/s41431-018-0135-1","volume":"26","author":"C Michot","year":"2018","unstructured":"Michot C, Le Goff C, Blair E, Blanchet P, Capri Y, Gilbert-Dussardier B, et al. Expanding the phenotypic spectrum of variants in PDE4D\/PRKAR1A: from acrodysostosis to acroscyphodysplasia. Eur J Hum Genet. 2018;26:1611\u201322.","journal-title":"Eur J Hum Genet."},{"key":"997_CR49","first-page":"587","volume":"27","author":"H-T Zhang","year":"2002","unstructured":"Zhang H-T, Huang Y, Jin S-L, Frith SA, Suvarna N, Conti M, et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology. 2002;27:587\u201395.","journal-title":"Neuropsychopharmacology."},{"key":"997_CR50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.neuropharm.2007.10.009","volume":"54","author":"JA Siuciak","year":"2008","unstructured":"Siuciak JA, McCarthy SA, Chapin DS, Martin AN, Harms JF, Schmidt CJ. Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57\/Bl6N congenic background. Neuropharmacology. 2008;54:417\u201327.","journal-title":"Neuropharmacology."},{"key":"997_CR51","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/cns.12834","volume":"24","author":"A Cardinale","year":"2018","unstructured":"Cardinale A, Fusco FR. Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington\u2019s disease. CNS Neurosci Ther. 2018;24:319\u201328.","journal-title":"CNS Neurosci Ther."},{"key":"997_CR52","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12035-016-0355-8","volume":"55","author":"DN Nthenge-Ngumbau","year":"2018","unstructured":"Nthenge-Ngumbau DN, Mohanakumar KP. Can cyclic nucleotide phosphodiesterase inhibitors be drugs for Parkinson\u2019s disease? Mol Neurobiol. 2018;55:822\u201334.","journal-title":"Mol Neurobiol"},{"key":"997_CR53","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/iub.1104","volume":"64","author":"E Bollen","year":"2012","unstructured":"Bollen E, Prickaerts J. Phosphodiesterases in neurodegenerative disorders. IUBMB Life. 2012;64:965\u201370.","journal-title":"IUBMB Life."},{"key":"997_CR54","doi-asserted-by":"publisher","first-page":"8457","DOI":"10.1073\/pnas.1000730107","volume":"107","author":"MP Kelly","year":"2010","unstructured":"Kelly MP, Logue SF, Brennan J, Day JP, Lakkaraju S, Jiang L, et al. Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes. Proc Natl Acad Sci USA. 2010;107:8457\u201362.","journal-title":"Proc Natl Acad Sci USA."},{"key":"997_CR55","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-3-319-58811-7_8","volume":"17","author":"MP Kelly","year":"2017","unstructured":"Kelly MP. A role for phosphodiesterase 11A (PDE11A) in the formation of social memories and the stabilization of mood. Adv Neurobiol. 2017;17:201\u201330.","journal-title":"Adv Neurobiol."},{"key":"997_CR56","first-page":"163","volume":"5","author":"H-R Luo","year":"2009","unstructured":"Luo H-R, Wu G-S, Dong C, Arcos-Burgos M, Ribeiro L, Licinio J, et al. Association of PDE11A global haplotype with major depression and antidepressant drug response. Neuropsychiatr Dis Treat. 2009;5:163\u201370.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"997_CR57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/WNR.0b013e328321b5a0","volume":"20","author":"GW Reierson","year":"2009","unstructured":"Reierson GW, Mastronardi CA, Licinio J, Wong M-L. Chronic imipramine downregulates cyclic AMP signaling in rat hippocampus. Neuroreport. 2009;20:307\u201311.","journal-title":"Neuroreport."},{"key":"997_CR58","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.neulet.2009.09.047","volume":"466","author":"GW Reierson","year":"2009","unstructured":"Reierson GW, Mastronardi CA, Licinio J, Wong M-L. Repeated antidepressant therapy increases cyclic GMP signaling in rat hippocampus. Neurosci Lett. 2009;466:149\u201353.","journal-title":"Neurosci Lett."},{"key":"997_CR59","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1124\/jpet.119.260869","volume":"371","author":"T Enomoto","year":"2019","unstructured":"Enomoto T, Tatara A, Goda M, Nishizato Y, Nishigori K, Kitamura A, et al. A novel phosphodiesterase 1 inhibitor DSR-141562 exhibits efficacies in animal models for positive, negative, and cognitive symptoms associated with schizophrenia. J Pharmacol Exp Ther. 2019;371:692\u2013702.","journal-title":"J Pharmacol Exp Ther."},{"key":"997_CR60","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/cns.12863","volume":"24","author":"L Liu","year":"2018","unstructured":"Liu L, Zheng J, Huang X-F, Zhu X, Ding S-M, Ke H-M, et al. The neuroprotective and antidepressant-like effects of Hcyb1, a novel selective PDE2 inhibitor. CNS Neurosci Ther. 2018;24:652\u201360.","journal-title":"CNS Neurosci Ther."},{"key":"997_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1124\/jpet.117.245506","volume":"365","author":"M Nakashima","year":"2018","unstructured":"Nakashima M, Imada H, Shiraishi E, Ito Y, Suzuki N, Miyamoto M, et al. Phosphodiesterase 2A inhibitor TAK-915 ameliorates cognitive impairments and social withdrawal in N-methyl-d-aspartate receptor antagonist-induced rat models of schizophrenia. J Pharmacol Exp Ther. 2018;365:179\u201388.","journal-title":"J Pharmacol Exp Ther."},{"key":"997_CR62","doi-asserted-by":"publisher","first-page":"112192","DOI":"10.1016\/j.bbr.2019.112192","volume":"376","author":"M Nakashima","year":"2019","unstructured":"Nakashima M, Suzuki N, Shiraishi E, Iwashita H. TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models. Behav Brain Res. 2019;376:112192.","journal-title":"Behav Brain Res."},{"key":"997_CR63","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00586-017-5023-9","volume":"26","author":"J-N Wang","year":"2017","unstructured":"Wang J-N, Zhao X-J, Liu Z-H, Zhao X-L, Sun T, Fu Z-J. Selective phosphodiesterase-2A inhibitor alleviates radicular inflammation and mechanical allodynia in non-compressive lumbar disc herniation rats. Eur Spine J. 2017;26:1961\u20138.","journal-title":"Eur Spine J."},{"key":"997_CR64","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.neuropharm.2004.07.040","volume":"47","author":"FG Boess","year":"2004","unstructured":"Boess FG, Hendrix M, van der Staay F-J, Erb C, Schreiber R, van Staveren W, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology. 2004;47:1081\u201392.","journal-title":"Neuropharmacology."},{"key":"997_CR65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.brainres.2008.02.108","volume":"1216","author":"K Domek-\u0141opaci\u0144ska","year":"2008","unstructured":"Domek-\u0141opaci\u0144ska K, Strosznajder JB. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res. 2008;1216:68\u201377.","journal-title":"Brain Res."},{"key":"997_CR66","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.neuropharm.2015.04.008","volume":"95","author":"E Bollen","year":"2015","unstructured":"Bollen E, Akkerman S, Puzzo D, Gulisano W, Palmeri A, D\u2019Hooge R, et al. Object memory enhancement by combining sub-efficacious doses of specific phosphodiesterase inhibitors. Neuropharmacology. 2015;95:361\u20136.","journal-title":"Neuropharmacology."},{"key":"997_CR67","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3389\/fncel.2019.00432","volume":"13","author":"L Ruan","year":"2019","unstructured":"Ruan L, Du K, Tao M, Shan C, Ye R, Tang Y, et al. Phosphodiesterase-2 Inhibitor Bay 60-7550 ameliorates A\u03b2-induced cognitive and memory impairment via regulation of the HPA axis. Front Cell Neurosci. 2019;13:432.","journal-title":"Front Cell Neurosci."},{"key":"997_CR68","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/ejn.13461","volume":"45","author":"LM Soares","year":"2017","unstructured":"Soares LM, Meyer E, Milani H, Steinbusch HWM, Prickaerts J, de Oliveira RMW. The phosphodiesterase type 2 inhibitor BAY 60-7550 reverses functional impairments induced by brain ischemia by decreasing hippocampal neurodegeneration and enhancing hippocampal neuronal plasticity. Eur J Neurosci. 2017;45:510\u201320.","journal-title":"Eur J Neurosci."},{"key":"997_CR69","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s00213-018-4934-4","volume":"235","author":"J Shi","year":"2018","unstructured":"Shi J, Liu H, Pan J, Chen J, Zhang N, Liu K, et al. Inhibition of phosphodiesterase 2 by Bay 60-7550 decreases ethanol intake and preference in mice. Psychopharmacology. 2018;235:2377\u201385.","journal-title":"Psychopharmacology."},{"key":"997_CR70","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bbr.2012.08.019","volume":"236","author":"OAH Reneerkens","year":"2013","unstructured":"Reneerkens OAH, Rutten K, Bollen E, Hage T, Blokland A, Steinbusch HWM, et al. Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behav Brain Res. 2013;236:16\u201322.","journal-title":"Behav Brain Res."},{"key":"997_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08070-2","volume":"7","author":"L Wang","year":"2017","unstructured":"Wang L, Xiaokaiti Y, Wang G, Xu X, Chen L, Huang X, et al. Inhibition of PDE2 reverses beta amyloid induced memory impairment through regulation of PKA\/PKG-dependent neuro-inflammatory and apoptotic pathways. Sci Rep. 2017;7:12044.","journal-title":"Sci Rep."},{"key":"997_CR72","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1093\/cercor\/bhy192","volume":"29","author":"T Maurin","year":"2019","unstructured":"Maurin T, Melancia F, Jarjat M, Castro L, Costa L, Delhaye S, et al. Involvement of phosphodiesterase 2A activity in the pathophysiology of fragile X syndrome. Cereb Cortex. 2019;29:3241\u201352.","journal-title":"Cereb Cortex"},{"key":"997_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04082-0","volume":"7","author":"A Kitamura","year":"2017","unstructured":"Kitamura A, Manso Y, Duncombe J, Searcy J, Koudelka J, Binnie M, et al. Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion. Sci Rep. 2017;7:4299.","journal-title":"Sci Rep."},{"key":"997_CR74","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s13311-017-0512-4","volume":"14","author":"S-Y Tai","year":"2017","unstructured":"Tai S-Y, Chien C-Y, Chang Y-H, Yang Y-H. Cilostazol use is associated with reduced risk of dementia: a nationwide cohort study. Neurotherapeutics. 2017;14:784\u201391.","journal-title":"Neurotherapeutics."},{"key":"997_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0800-y","volume":"17","author":"S-Y Tai","year":"2017","unstructured":"Tai S-Y, Chen C-H, Chien C-Y, Yang Y-H. Cilostazol as an add-on therapy for patients with Alzheimer\u2019s disease in Taiwan: a case control study. BMC Neurol. 2017;17:40.","journal-title":"BMC Neurol."},{"key":"997_CR76","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuropharm.2009.12.008","volume":"58","author":"J Zhao","year":"2010","unstructured":"Zhao J, Harada N, Kurihara H, Nakagata N, Okajima K. Cilostazol improves cognitive function in mice by increasing the production of insulin-like growth factor-I in the hippocampus. Neuropharmacology. 2010;58:774\u201383.","journal-title":"Neuropharmacology."},{"key":"997_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-7-51","volume":"7","author":"W-H Zheng","year":"2006","unstructured":"Zheng W-H, Quirion R. Insulin-like growth factor-1 (IGF-1) induces the activation\/phosphorylation of Akt kinase and cAMP response element-binding protein (CREB) by activating different signaling pathways in PC12 cells. BMC Neurosci. 2006;7:51.","journal-title":"BMC Neurosci"},{"key":"997_CR78","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neurobiolaging.2019.01.014","volume":"77","author":"A Blokland","year":"2019","unstructured":"Blokland A, Van Duinen MA, Sambeth A, Heckman PRA, Tsai M, Lahu G, et al. Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study. Neurobiol Aging. 2019;77:37\u201343.","journal-title":"Neurobiol Aging."},{"key":"997_CR79","doi-asserted-by":"publisher","unstructured":"Gilleen J, Farah Y, Davison C, Kerins S, Valdearenas L, Uz T, et al. An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients. Psychopharmacology. 2018. https:\/\/doi.org\/10.1007\/s00213-018-5134-y.","DOI":"10.1007\/s00213-018-5134-y"},{"key":"997_CR80","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pnpbp.2018.10.017","volume":"90","author":"Q Zhong","year":"2019","unstructured":"Zhong Q, Yu H, Huang C, Zhong J, Wang H, Xu J, et al. FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress. Prog Neuropsychopharmacol Biol Psychiatry. 2019;90:62\u201375.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"997_CR81","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/sj.npp.1300813","volume":"31","author":"B Monti","year":"2006","unstructured":"Monti B, Berteotti C, Contestabile A. Subchronic Rolipram delivery activates hippocampal CREB and Arc, enhances retention and slows down extinction of conditioned fear. Neuropsychopharmacology 2006;31:278\u201386.","journal-title":"Neuropsychopharmacology"},{"key":"997_CR82","doi-asserted-by":"publisher","first-page":"107168","DOI":"10.1016\/j.nlm.2020.107168","volume":"169","author":"ME Wimmer","year":"2020","unstructured":"Wimmer ME, Blackwell JM, Abel T. Rolipram treatment during consolidation ameliorates long-term object location memory in aged male mice. Neurobiol Learn Mem. 2020;169:107168.","journal-title":"Neurobiol Learn Mem."},{"key":"997_CR83","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fnagi.2018.00204","volume":"10","author":"Y Xu","year":"2018","unstructured":"Xu Y, Zhu N, Xu W, Ye H, Liu K, Wu F, et al. Inhibition of phosphodiesterase-4 reverses A\u03b2-induced memory impairment by regulation of HPA axis related cAMP signaling. Front Aging Neurosci. 2018;10:204.","journal-title":"Front Aging Neurosci."},{"key":"997_CR84","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1124\/jpet.119.259986","volume":"371","author":"S-Y Cui","year":"2019","unstructured":"Cui S-Y, Yang M-X, Zhang Y-H, Zheng V, Zhang H-T, Gurney ME, et al. Protection from amyloid \u03b2 peptide-induced memory, biochemical, and morphological deficits by a phosphodiesterase-4D allosteric inhibitor. J Pharmacol Exp Ther. 2019;371:250\u20139.","journal-title":"J Pharmacol Exp Ther."},{"key":"997_CR85","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1038\/s41386-018-0178-6","volume":"43","author":"C Zhang","year":"2018","unstructured":"Zhang C, Xu Y, Chowdhary A, Fox D, Gurney ME, Zhang H-T, et al. Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice. Neuropsychopharmacology. 2018;43:2299\u2013309.","journal-title":"Neuropsychopharmacology."},{"key":"997_CR86","doi-asserted-by":"publisher","first-page":"10518","DOI":"10.1073\/pnas.1834280100","volume":"100","author":"R Bourtchouladze","year":"2003","unstructured":"Bourtchouladze R, Lidge R, Catapano R, Stanley J, Gossweiler S, Romashko D, et al. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci USA. 2003;100:10518\u201322.","journal-title":"Proc Natl Acad Sci USA."},{"key":"997_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.17","volume":"2","author":"V Wiescholleck","year":"2012","unstructured":"Wiescholleck V, Manahan-Vaughan D. PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis. Transl Psychiatry. 2012;2:e89.","journal-title":"Transl Psychiatry."},{"key":"997_CR88","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1523\/JNEUROSCI.1356-12.2015","volume":"35","author":"CH Choi","year":"2015","unstructured":"Choi CH, Schoenfeld BP, Weisz ED, Bell AJ, Chambers DB, Hinchey J, et al. PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome. J Neurosci. 2015;35:396\u2013408.","journal-title":"J Neurosci."},{"key":"997_CR89","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1161\/01.STR.0000034399.95249.59","volume":"33","author":"R Zhang","year":"2002","unstructured":"Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke. 2002;33:2675\u201380.","journal-title":"Stroke."},{"key":"997_CR90","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0306-4522(02)00199-9","volume":"113","author":"J Prickaerts","year":"2002","unstructured":"Prickaerts J, van Staveren WCG, Sik A, Markerink-van Ittersum M, Niew\u00f6hner U, van der Staay FJ, et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience. 2002;113:351\u201361.","journal-title":"Neuroscience."},{"key":"997_CR91","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00213-005-0232-z","volume":"183","author":"BD Devan","year":"2006","unstructured":"Devan BD, Bowker JL, Duffy KB, Bharati IS, Jimenez M, Sierra-Mercado D, et al. Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition. Psychopharmacology. 2006;183:439\u201345.","journal-title":"Psychopharmacology."},{"key":"997_CR92","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/ADR-200166","volume":"4","author":"O Sanders","year":"2020","unstructured":"Sanders O. Sildenafil for the treatment of Alzheimer\u2019s disease: a systematic review. J Alzheimers Dis Rep. 2020;4:91\u2013106.","journal-title":"J Alzheimers Dis Rep"},{"key":"997_CR93","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/PL00007092","volume":"19","author":"D Schultheiss","year":"2001","unstructured":"Schultheiss D, M\u00fcller SV, Nager W, Stief CG, Schlote N, Jonas U, et al. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World J Urol. 2001;19:46\u201350.","journal-title":"World J Urol."},{"key":"997_CR94","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/cns.12864","volume":"24","author":"X-F Huang","year":"2018","unstructured":"Huang X-F, Jiang W-T, Liu L, Song F-C, Zhu X, Shi G-L, et al. A novel PDE9 inhibitor WYQ-C36D ameliorates corticosterone-induced neurotoxicity and depression-like behaviors by cGMP-CREB-related signaling. CNS Neurosci Ther. 2018;24:889\u201396.","journal-title":"CNS Neurosci Ther."},{"key":"997_CR95","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1124\/jpet.111.191353","volume":"341","author":"RJ Kleiman","year":"2012","unstructured":"Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, et al. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharmacol Exp Ther. 2012;341:396\u2013409.","journal-title":"J Pharmacol Exp Ther"},{"key":"997_CR96","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-019-0467-2","volume":"11","author":"L Fr\u00f6lich","year":"2019","unstructured":"Fr\u00f6lich L, Wunderlich G, Thamer C, Roehrle M, Garcia M, Dubois B. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11:18.","journal-title":"Alzheimers Res Ther."},{"key":"997_CR97","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2174\/1567205011666140505100858","volume":"11","author":"EM Schwam","year":"2014","unstructured":"Schwam EM, Nicholas T, Chew R, Billing CB, Davidson W, Ambrose D, et al. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer\u2019s disease. Curr Alzheimer Res. 2014;11:413\u201321.","journal-title":"Curr Alzheimer Res."},{"key":"997_CR98","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3389\/fnins.2020.00466","volume":"14","author":"S Chakroborty","year":"2020","unstructured":"Chakroborty S, Manfredsson FP, Dec AM, Campbell PW, Stutzmann GE, Beaumont V, et al. Phosphodiesterase 9A inhibition facilitates corticostriatal transmission in wild-type and transgenic rats that model Huntington\u2019s disease. Front Neurosci. 2020;14:466.","journal-title":"Front Neurosci"},{"key":"997_CR99","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/jpet.114.218552","volume":"352","author":"K Suzuki","year":"2015","unstructured":"Suzuki K, Harada A, Shiraishi E, Kimura H. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents. J Pharmpacol Exp Ther. 2015;352:471\u20139.","journal-title":"J Pharmpacol Exp Ther"},{"key":"997_CR100","doi-asserted-by":"publisher","first-page":"172757","DOI":"10.1016\/j.pbb.2019.172757","volume":"185","author":"M Takakuwa","year":"2019","unstructured":"Takakuwa M, Watanabe Y, Tanaka K, Ishii T, Kagaya K, Taniguchi H, et al. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents. Pharmacol Biochem Behav. 2019;185:172757.","journal-title":"Pharmacol Biochem Behav"},{"key":"997_CR101","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.schres.2018.08.028","volume":"204","author":"TA Macek","year":"2019","unstructured":"Macek TA, McCue M, Dong X, Hanson E, Goldsmith P, Affinito J, et al. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophrenia Res. 2019;204:289\u201394.","journal-title":"Schizophrenia Res."},{"key":"997_CR102","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/s41593-018-0261-7","volume":"21","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, Wang Z-M, Tan W, Wang X, Li Y, Bai B, et al. Partial loss of psychiatric risk gene miR-137 in mice causes repetitive behavior and impairs sociability and learning via increased Pde10a. Nat Neurosci. 2018;21:1689\u2013703.","journal-title":"Nat Neurosci."},{"key":"997_CR103","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/hipo.22128","volume":"23","author":"A Giralt","year":"2013","unstructured":"Giralt A, Saavedra A, Carret\u00f3n O, Arum\u00ed H, Tyebji S, Alberch J, et al. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington\u2019s disease mouse model. Hippocampus. 2013;23:684\u201395.","journal-title":"Hippocampus."},{"key":"997_CR104","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3389\/fncel.2018.00470","volume":"12","author":"S Guang","year":"2018","unstructured":"Guang S, Pang N, Deng X, Yang L, He F, Wu L, et al. Synaptopathology involved in autism spectrum disorder. Front Cell Neurosci. 2018;12:470.","journal-title":"Front Cell Neurosci."},{"key":"997_CR105","doi-asserted-by":"publisher","unstructured":"Luhach K, Kulkarni GT, Singh VP, Sharma B. Attenuation of neurobehavioural abnormalities by papaverine in prenatal valproic acid rat model of ASD. Eur J Pharmacol. 2020:173663. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173663","DOI":"10.1016\/j.ejphar.2020.173663"},{"key":"997_CR106","doi-asserted-by":"publisher","unstructured":"Sharma N, Dhiman N, Golani LK, Sharma B. Papaverine ameliorates prenatal alcohol-induced experimental attention deficit hyperactivity disorder by regulating neuronal function, inflammation, and oxidative stress. Int J Dev Neurosci. 2020; https:\/\/doi.org\/10.1002\/jdn.10076.","DOI":"10.1002\/jdn.10076"},{"key":"997_CR107","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-019-0143-7","volume":"6","author":"SE Antonarakis","year":"2020","unstructured":"Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, et al. Down syndrome. Nat Rev Dis Prim. 2020;6:9.","journal-title":"Nat Rev Dis Prim"},{"key":"997_CR108","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3389\/fnmol.2019.00272","volume":"12","author":"I De Toma","year":"2019","unstructured":"De Toma I, Ortega M, Aloy P, Sabid\u00f3 E, Dierssen M. DYRK1A overexpression alters cognition and neural-related proteomic pathways in the hippocampus that are rescued by green tea extract and\/or environmental enrichment. Front Mol Neurosci. 2019;12:272.","journal-title":"Front Mol Neurosci."},{"key":"997_CR109","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/mp.2015.5","volume":"21","author":"BWM van Bon","year":"2016","unstructured":"van Bon BWM, Coe BP, Bernier R, Green C, Gerdts J, Witherspoon K, et al. Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID. Mol Psychiatry. 2016;21:126\u201332.","journal-title":"Mol Psychiatry."},{"key":"997_CR110","doi-asserted-by":"publisher","first-page":"39819","DOI":"10.1074\/jbc.M104091200","volume":"276","author":"EJ Yang","year":"2001","unstructured":"Yang EJ, Ahn YS, Chung KC. Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells. J Biol Chem. 2001;276:39819\u201324.","journal-title":"J Biol Chem"},{"key":"997_CR111","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41582-018-0132-6","volume":"15","author":"IT Lott","year":"2019","unstructured":"Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019;15:135\u201347.","journal-title":"Nat Rev Neurol."},{"key":"997_CR112","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0006-8993(96)01173-0","volume":"749","author":"M Dierssen","year":"1997","unstructured":"Dierssen M, Vallina IF, Baamonde C, Garc\u00eda-Calatayud S, Lumbreras MA, Fl\u00f3rez J. Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome. Brain Res. 1997;749:238\u201344.","journal-title":"Brain Res."},{"key":"997_CR113","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3389\/fnagi.2020.00106","volume":"12","author":"M Tsuji","year":"2020","unstructured":"Tsuji M, Ohshima M, Yamamoto Y, Saito S, Hattori Y, Tanaka E, et al. Cilostazol, a phosphodiesterase 3 inhibitor, moderately attenuates behaviors depending on sex in the Ts65Dn mouse model of down syndrome. Front Aging Neurosci. 2020;12:106.","journal-title":"Front Aging Neurosci."},{"key":"997_CR114","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fnmol.2018.00041","volume":"11","author":"R Dahlhaus","year":"2018","unstructured":"Dahlhaus R. Of men and mice: modeling the fragile X syndrome. Front Mol Neurosci 2018;11:41.","journal-title":"Front Mol Neurosci"},{"key":"997_CR115","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ana.410310105","volume":"31","author":"E Berry-Kravis","year":"1992","unstructured":"Berry-Kravis E, Huttenlocher PR. Cyclic AMP metabolism in fragile X syndrome. Ann Neurol. 1992;31:22\u201326.","journal-title":"Ann Neurol."},{"key":"997_CR116","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1093\/nar\/gky267","volume":"46","author":"T Maurin","year":"2018","unstructured":"Maurin T, Lebrigand K, Castagnola S, Paquet A, Jarjat M, Popa A, et al. HITS-CLIP in various brain areas reveals new targets and new modalities of RNA binding by fragile X mental retardation protein. Nucleic Acids Res. 2018;46:6344\u201355.","journal-title":"Nucleic Acids Res."},{"key":"997_CR117","doi-asserted-by":"publisher","first-page":"104482","DOI":"10.1016\/j.nbd.2019.104482","volume":"130","author":"N Garc\u00eda-Font","year":"2019","unstructured":"Garc\u00eda-Font N, Mart\u00edn R, Torres M, Oset-Gasque MJ, S\u00e1nchez-Prieto J. The loss of \u03b2 adrenergic receptor mediated release potentiation in a mouse model of fragile X syndrome. Neurobiol Dis. 2019;130:104482.","journal-title":"Neurobiol Dis."},{"key":"997_CR118","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.neuron.2013.02.027","volume":"78","author":"J Boyken","year":"2013","unstructured":"Boyken J, Gr\u00f8nborg M, Riedel D, Urlaub H, Jahn R, Chua JJE. Molecular profiling of synaptic vesicle docking sites reveals novel proteins but few differences between glutamatergic and GABAergic synapses. Neuron. 2013;78:285\u201397.","journal-title":"Neuron."},{"key":"997_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15028-x","volume":"7","author":"ME Gurney","year":"2017","unstructured":"Gurney ME, Cogram P, Deacon RM, Rex C, Tranfaglia M. Multiple behavior phenotypes of the fragile-X syndrome mouse model respond to chronic inhibition of phosphodiesterase-4D (PDE4D). Sci Rep. 2017;7:14653.","journal-title":"Sci Rep."},{"key":"997_CR120","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.celrep.2014.06.039","volume":"8","author":"MC Manzini","year":"2014","unstructured":"Manzini MC, Xiong L, Shaheen R, Tambunan DE, Di Costanzo S, Mitisalis V, et al. CC2D1A regulates human intellectual and social function as well as NF-\u03baB signaling homeostasis. Cell Rep. 2014;8:647\u201355.","journal-title":"Cell Rep."},{"key":"997_CR121","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.devcel.2006.09.014","volume":"11","author":"CM Gallagher","year":"2006","unstructured":"Gallagher CM, Knoblich JA. The conserved c2 domain protein lethal (2) giant discs regulates protein trafficking in Drosophila. Dev Cell. 2006;11:641\u201353.","journal-title":"Dev Cell."},{"key":"997_CR122","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/cercor\/bhw009","volume":"27","author":"AW Oaks","year":"2017","unstructured":"Oaks AW, Zamarbide M, Tambunan DE, Santini E, Di Costanzo S, Pond HL, et al. Cc2d1a Loss of function disrupts functional and morphological development in forebrain neurons leading to cognitive and social deficits. Cereb Cortex. 2017;27:1670\u201385.","journal-title":"Cereb Cortex."},{"key":"997_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/srep38048","volume":"6","author":"F Guan","year":"2016","unstructured":"Guan F, Lin H, Chen G, Li L, Chen T, Liu X, et al. Evaluation of association of common variants in HTR1A and HTR5A with schizophrenia and executive function. Sci Rep. 2016;6:38048.","journal-title":"Sci Rep."},{"key":"997_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-11-47","volume":"11","author":"A Al-Tawashi","year":"2013","unstructured":"Al-Tawashi A, Gehring C. Phosphodiesterase activity is regulated by CC2D1A that is implicated in non-syndromic intellectual disability. Cell Commun Signal. 2013;11:47.","journal-title":"Cell Commun Signal."},{"key":"997_CR125","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.biopsych.2018.12.013","volume":"85","author":"M Zamarbide","year":"2019","unstructured":"Zamarbide M, Mossa A, Mu\u00f1oz-Llancao P, Wilkinson MK, Pond HL, Oaks AW, et al. Male-specific cAMP signaling in the hippocampus controls spatial memory deficits in a mouse model of autism and intellectual disability. Biol Psychiatry. 2019;85:760\u20138.","journal-title":"Biol Psychiatry."},{"key":"997_CR126","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1172\/JCI78167","volume":"125","author":"LM Lombardi","year":"2015","unstructured":"Lombardi LM, Baker SA, Zoghbi HY. MECP2 disorders: from the clinic to mice and back. J Clin Investig. 2015;125:2914\u201323.","journal-title":"J Clin Investig."},{"key":"997_CR127","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.neuroscience.2019.06.013","volume":"413","author":"A Sanfeliu","year":"2019","unstructured":"Sanfeliu A, Kaufmann WE, Gill M, Guasoni P, Tropea D. Transcriptomic studies in mouse models of Rett syndrome: a review. Neuroscience. 2019;413:183\u2013205.","journal-title":"Neuroscience."},{"key":"997_CR128","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.neuropharm.2011.01.002","volume":"60","author":"SL Mironov","year":"2011","unstructured":"Mironov SL, Skorova EY, K\u00fcgler S. Epac-mediated cAMP-signalling in the mouse model of Rett Syndrome. Neuropharmacology. 2011;60:869\u201377.","journal-title":"Neuropharmacology."},{"key":"997_CR129","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1523\/JNEUROSCI.3735-16.2017","volume":"37","author":"Q Bu","year":"2017","unstructured":"Bu Q, Wang A, Hamzah H, Waldman A, Jiang K, Dong Q, et al. CREB Signaling Is Involved in Rett Syndrome Pathogenesis. J Neurosci. 2017;37:3671\u201385.","journal-title":"J Neurosci."},{"key":"997_CR130","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/07853890802441169","volume":"41","author":"K Esposito","year":"2009","unstructured":"Esposito K, Reierson GW, Luo HR, Wu GS, Licinio J, Wong M-L. Phosphodiesterase genes and antidepressant treatment response: a review. Ann Med. 2009;41:177\u201385.","journal-title":"Ann Med."},{"key":"997_CR131","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.2174\/138161206777698855","volume":"12","author":"A Blokland","year":"2006","unstructured":"Blokland A, Schreiber R, Prickaerts J. Improving memory: a role for phosphodiesterases. Curr Pharm Des. 2006;12:2511\u201323.","journal-title":"Curr Pharm Des."},{"key":"997_CR132","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","volume":"26","author":"J Prickaerts","year":"2017","unstructured":"Prickaerts J, Heckman PRA, Blokland A. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer\u2019s disease. Expert Opin Investig Drugs. 2017;26:1033\u201348.","journal-title":"Expert Opin Investig Drugs."},{"key":"997_CR133","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.nlm.2014.10.011","volume":"119","author":"PRA Heckman","year":"2015","unstructured":"Heckman PRA, Blokland A, Ramaekers J, Prickaerts J. PDE and cognitive processing: beyond the memory domain. Neurobiol Learn Mem. 2015;119:108\u201322.","journal-title":"Neurobiol Learn Mem."},{"key":"997_CR134","doi-asserted-by":"publisher","first-page":"21","DOI":"10.21307\/ane-2018-005","volume":"78","author":"G Bj\u00f8rklund","year":"2018","unstructured":"Bj\u00f8rklund G, Kern JK, Urbina MA, Saad K, El-Houfey AA, Geier DA, et al. Cerebral hypoperfusion in autism spectrum disorder. Acta Neurobiol Exp. 2018;78:21\u201329.","journal-title":"Acta Neurobiol Exp."},{"key":"997_CR135","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.lfs.2006.02.026","volume":"79","author":"S Pieretti","year":"2006","unstructured":"Pieretti S, Dominici L, Di Giannuario A, Cesari N, Dal Piaz V. Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors. Life Sci. 2006;79:791\u2013800.","journal-title":"Life Sci."},{"key":"997_CR136","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bbi.2019.04.037","volume":"79","author":"SM Matta","year":"2019","unstructured":"Matta SM, Hill-Yardin EL, Crack PJ. The influence of neuroinflammation in Autism Spectrum Disorder. Brain Behav Immun. 2019;79:75\u201390.","journal-title":"Brain Behav Immun."},{"key":"997_CR137","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrneurol.2015.13","volume":"11","author":"H Hagberg","year":"2015","unstructured":"Hagberg H, Mallard C, Ferriero DM, Vannucci SJ, Levison SW, Vexler ZS, et al. The role of inflammation in perinatal brain injury. Nat Rev Neurol. 2015;11:192\u2013208.","journal-title":"Nat Rev Neurol."},{"key":"997_CR138","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1042\/BST0331323","volume":"33","author":"M Zaccolo","year":"2005","unstructured":"Zaccolo M, Cesetti T, Di Benedetto G, Mongillo M, Lissandron V, Terrin A, et al. Imaging the cAMP-dependent signal transduction pathway. Biochem Soc Trans. 2005;33:1323\u20136.","journal-title":"Biochem Soc Trans."},{"key":"997_CR139","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.1113\/JP270675","volume":"594","author":"L Ferron","year":"2016","unstructured":"Ferron L. Fragile X mental retardation protein controls ion channel expression and activity. J Physiol. 2016;594:5861\u20137.","journal-title":"J Physiol."},{"key":"997_CR140","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1101\/gr.262717.120","volume":"30","author":"S Castagnola","year":"2020","unstructured":"Castagnola S, Cazareth J, Lebrigand K, Jarjat M, Magnone V, Delhaye S, et al. Agonist-induced functional analysis and cell sorting associated with single-cell transcriptomics characterizes cell subtypes in normal and pathological brain. Genome Res. 2020;30:1633\u201342.","journal-title":"Genome Res."},{"key":"997_CR141","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fncel.2017.00014","volume":"11","author":"S Wrigley","year":"2017","unstructured":"Wrigley S, Arafa D, Tropea D. Insulin-like growth factor 1: at the crossroads of brain development and aging. Front Cell Neurosci. 2017;11:14.","journal-title":"Front Cell Neurosci"},{"key":"997_CR142","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12017-015-8341-2","volume":"17","author":"RMJ Deacon","year":"2015","unstructured":"Deacon RMJ, Glass L, Snape M, Hurley MJ, Altimiras FJ, Biekofsky RR, et al. NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome. Neuromolecular Med. 2015;17:71\u201382.","journal-title":"Neuromolecular Med."},{"key":"997_CR143","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1523\/JNEUROSCI.0367-19.2019","volume":"40","author":"E-E Esvald","year":"2020","unstructured":"Esvald E-E, Tuvikene J, Sirp A, Patil S, Bramham CR, Timmusk T. CREB family transcription factors are major mediators of BDNF transcriptional autoregulation in cortical neurons. J Neurosci. 2020;40:1405\u201326.","journal-title":"J Neurosci"},{"key":"997_CR144","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2015.10.034","volume":"102","author":"C Bj\u00f6rkholm","year":"2016","unstructured":"Bj\u00f6rkholm C, Monteggia LM. BDNF\u2014a key transducer of antidepressant effects. Neuropharmacology. 2016;102:72\u201379.","journal-title":"Neuropharmacology."},{"key":"997_CR145","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.12740\/PP\/37705","volume":"49","author":"M Libman-Soko\u0142owska","year":"2015","unstructured":"Libman-Soko\u0142owska M, Drozdowicz E, Nasierowski T. BDNF as a biomarker in the course and treatment of schizophrenia. Psychiatr Pol. 2015;49:1149\u201358.","journal-title":"Psychiatr Pol"},{"key":"997_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0752-8","volume":"13","author":"J Downs","year":"2018","unstructured":"Downs J, Rodger J, Li C, Tan X, Hu N, Wong K, et al. Environmental enrichment intervention for Rett syndrome: an individually randomised stepped wedge trial. Orphanet J Rare Dis. 2018;13:3.","journal-title":"Orphanet J Rare Dis."},{"key":"997_CR147","doi-asserted-by":"publisher","first-page":"11298","DOI":"10.1523\/JNEUROSCI.2893-16.2017","volume":"37","author":"T Nomura","year":"2017","unstructured":"Nomura T, Musial TF, Marshall JJ, Zhu Y, Remmers CL, Xu J, et al. Delayed maturation of fast-spiking interneurons is rectified by activation of the TrkB receptor in the mouse model of fragile X syndrome. J Neurosci. 2017;37:11298\u2013310.","journal-title":"J Neurosci."},{"key":"997_CR148","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0378-1119(03)00733-9","volume":"314","author":"P Wang","year":"2003","unstructured":"Wang P, Wu P, Egan RW, Billah MM. Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5): differential tissue distribution and subcellular localization of PDE9A variants. Gene. 2003;314:15\u201327.","journal-title":"Gene."}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-00997-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-00997-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-00997-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T22:05:32Z","timestamp":1666735532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-00997-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":148,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["997"],"URL":"https:\/\/doi.org\/10.1038\/s41380-020-00997-9","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"4 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}